Even After Being a Continuous Process of Plantation and Manufacturing Tea Industry Not Exempted from Lockdown – Guwahati Plus

GUWAHATI: In the 21-day lockdown ordered by PM Narendra Modi to combat COVID-19, the ministry of home affairs has exempted a few services and businesses.

As per point number 5 of the order no. 40-3/2020 dated 24th March of the ministry, industrial establishments are to remain closed. The exceptions to this closure are:

a. Manufacturing units of essential commodities.b. Production units, which require continuous process, after obtaining required permission from the state government.

Despite this order, the tea industry of Assam has not been exempted from the lockdown.Given the fragile and perishable nature of the tea plants, the Assam Valley Branch of Consultative Committee of Plantation Associations had requested the Labour Commisssioner to exempt specific operations of the industry.

The application requested that tea gardens be allowed to work for the protection of the plants by spraying of pest repellents and pest killers as there might be huge and permanent damage to the plants during such a long closure period.

Further, irrigation of plants to be continued, given scanty rainfall during the period.

Dipanjol Deka, Secretary of Tea Association of India, speaking to G Plus informed, The Deputy Commissioner of some districts have allowed us to keep five workers per day per garden for the required work. However, all district authorities have not yet complied to our request.

Given that the tea plantation and manufacturing business is a continuous process, the state government should have exempted us from the lockdown, he added.

Nazrana Ahmed, President of Assam Tea Planters Association said, The tea industry was already in a crisis in the last two years, and from the beginning of this year there has been a drop of sale prices in the Gauhati Tea Auction by an average of Rs. 80 to Rs. 90 per kg.

Further, the tea industry is dealing with a very fragile and perishable commodity dependent on plant physiology and are infected by pests. The plucking is done on a round of every six to seven days. So during lock down these plants would grow about a foot long and has to be skiffed as these cannot be used for the manufacture of tea. We have to wait for regeneration of the bushes again. So a lock down of five days actually means about a month long lock down for the tea industry

As such given the three-week long lockdown the losses to be incurred by the industry could be highly extensive.

Originally posted here:
Even After Being a Continuous Process of Plantation and Manufacturing Tea Industry Not Exempted from Lockdown - Guwahati Plus

Immunology and Numerology | DG Hart – Patheos

Lots of people are panicking about the spread and threat of COVID-19. Among those fearful is Angelo Cataldi, a sports-talk radio host on Philadelphias 94WIP. One of the reasons Cataldi and his morning team are still on the air is that Pennsylvanias governor, Tom Wolf, deemed radio stations an essential business. To its credit, the station regularly plays either public service announcements about washing hands (and more) or reports news about the pandemic.

One of the seeming misunderstandings about this virus is the mortality rate. The way Cataldi usually reacts to news that one of his co-works is symptomatic or that a sports celebrity being tested positive (like Rudy Gobert) is as if he had heard that someone heard the sentence of cancer. With governors and health authorities projecting millions of cases, and with largely high-end attention to every single death from the disease (in ways similar to nightly reports by Walter Cronkite about the Vietnam War), Cataldi may be spared of blame. All the news sounds horrible. Thats why the response of shutting down businesses seems proportionate.

The problem is that people are paying attention to a very small range of numbers. Italy is arguably the worst case of the COVID-19 outbreak and so far the nation has almost 70,000 cases with the astounding result of 6,800 deaths. [All of these dates are from March 24, 2020.] That is twice as many deaths as China (3,281), though reporting from the country in which the virus originated is largely unreliable. Compared to the United States (674), Italy has ten times the number of deaths and almost thirty-three percent more cases (the US has almost 50,000 cases). An important data point to keep in mind is the mortality rate. In the case of Italy, the rate is close to 10 percent, which is extraordinarily high. It is not as high as the mortality rates for Ebola (50%), MERS (33%), or polio (20%). But it is much higher than seasonal flu (0.1%). Even so, if you project Italys numbers onto the United States, with .0001 percent (7,000 cases out of 60,000,000 people) of Americans (320,000,000) getting the virus, that results in 320,000 total cases. A death rate of ten percent (roughly) projects to 32,000 deaths from COVID-19 in the United States. Thats a lot. But its also about the same number of people who die in auto accidents each year roughly 31,500. Imagine if newspapers and sports talk show hosts gave daily updates on the number of auto accident fatalities. Some people would likely be afraid to drive.

All of these numbers, though, are remarkably low when it comes to professional sports. Angelo Cataldi was rightly offended yesterday morning that Josh Harris, the owner of the Philadelphia Seventy-Sixers, had decided to cut staff (not players) salaries by twenty percent. The team later reversed its decision. The principal owner of the team, Harris, is reported to be worth $3.5 billion. Not a good look cutting five-figure salaries.

Hargrave: The biggest deal handed out by the Eagles so far was to defensive tackle Javon Hargrave, a three-year, $39 million deal. Over The Cap has the details of that contract.

The cap hits:

2020: $3.4 million

2021: $15.2 million

2022: $15.4 million

The cap hit in 2020 is small, but as you can see, it raises significantly in 2021.

The Hargrave deal costs the Eagles $3.4 million in cap space for 2020, bringing them down to around $40 million.

Rodney McLeod: The Eagles signed Rodney McLeod to a two-year, $12 million deal. The details on the cap hit are not yet known, but if you use the average of the contract, it will cost the Eagles $6 million in salary cap space, bringing them down to around $34 million.

Jalen Mills: Mills is back with the Eagles on a one-year deal that could be worth up to $5 million with incentives. His cap hit is going to be lower than the $5 million the deal could be worth, however, coming in at $4 million. The Mills signing brings the Eagles down to around $30 million in cap space.

$3 million compared to $39 million does seem small. And that is small compared to Tom Bradys $50 million deal with the Tampa Bay Bucs.

But wouldnt you think all those zeros in football player contracts might put 677 in perspective (number of deaths so far from COVID-19 in the US). Might you also be mindful of the astronomic salaries that professional athletes receive, compared to the ninety-nine percent, in an era when a socialist is one of the leading candidates for the Democratic Partys nominee for POTUS? Of course, death is awful and human life is much more valuable than dollars.

But when you are in the habit of counting, numbers could yield perspective. And so the number of deaths from this virus are comparatively small (Heart disease: 647,457; Cancer: 599,108; Accidents (unintentional injuries): 169,936; Chronic lower respiratory diseases: 160,201; Stroke (cerebrovascular diseases): 146,383; Alzheimers disease: 121,404.

Image

The rest is here:
Immunology and Numerology | DG Hart - Patheos

Berkeley Lights Announces the Global Emerging Pathogen Antibody Discovery Consortium (GEPAD) to Attack COVID-19 and Other Viruses – Yahoo Finance

In collaboration with Vanderbilt University Medical Center, La Jolla Institute for Immunology and Emory University, viral neutralization workflows on the Berkeley Lights platform are under accelerated development in response to the Coronavirus outbreak

EMERYVILLE, Calif., March 25, 2020 /PRNewswire/ --Today Berkeley Lights, Inc., announced the Global Emerging Pathogen Antibody Discovery Consortium (GEPAD) with founding members Dr. James Crowe and Dr. Robert Carnahan at Vanderbilt University Medical Center, Dr. Erica Ollman Saphire at La Jolla Institute for Immunology and Dr. Frances Eun-Hyung Lee at Emory University with the aim to accelerate the discovery of neutralizing antibodies from patient blood samples. Processing precious blood samples and fragile cells can be challenging with traditional technologies. The consortium will leverage Berkeley Lights' Beacon platform for antibody discovery using the blood of recovering patients as the foundation for therapeutics, with COVID-19 as a first target.

(PRNewsfoto/Berkeley Lights)

While researchers around the world are quickly characterizing the SARS-CoV-2 virus, the ability to screen single B cells expressing a SARS-CoV-2 neutralizing antibody remains a significant and time-consuming challenge.The body has billions of B cells. After a patient recovers from SAR-CoV-2, they generate many B cells specific for the virus; however, some B cells will make antibodies that just bind to the virus but are not protective. Hence, finding the special B cells that eliminate or neutralize the virus is exceedingly rare. It is like finding a "needle in a haystack". The existing technologies can only search for binders, not neutralizers so researchers are forced to sequence and re-express the antibody from non-specific B cells wasting significant time and resources. The Beacon system and the viral neutralization assay is designed to address this problem by directly screening single cells for neutralizing function in a single day.

The primary goal of the GEPAD Consortium is to enable the quickest therapeutic response to emerging pathogens. The GEPAD Consortium is requesting that anyone interested in this viral neutralization workflow and advancing the state of the art reach out and join them in forming a defensive barrier worldwide against diseases caused by emerging pathogens. Members will be enabled to rapidly discover potential treatments using small volume blood samples from recovering patientsboth acute and convalescent. The consortium is rapidly iterating and improving the viral neutralization workflow executing on the Berkeley Lights platform and hopes that more collaborators will come forward to participate in fighting this epidemic and be better prepared for the next one.

"We have long sought to study the antiviral capacity of antibodies secreted by single human B cells, but the instruments and protocols for doing those studies didn't exist. Partnering with Berkeley Lights on developing innovative approaches to this single-cell biology task is now becoming a reality," said Dr. James Crowe, MD, Director of the Vanderbilt Vaccine Center.

"We have developed a specialized survival media for plasma cells and envision the use of it for rapid upfront selection of a rare target monoclonal antibody," said Dr. Lee. "Berkeley Lights together with this consortium will make this method a reality for COVID-19 neutralizing antibodies. We hope this helps in this pandemic to save lives."

Story continues

"There's an opportunity here to quickly mobilize something that could protect frontline workers or treat those who have been infected," explained Dr. Saphire. "Vaccines aren't available yet. Providing some immediate immunity using antibodies could be lifesaving for those who haven't been vaccinated or can't be vaccinated, or if the eventual vaccines aren't completely protective."

"COVID-19 is a serious threat to our health, our way of life, and the world economy," said Dr. Eric Hobbs, CEO of Berkeley Lights. "We are committed to doing our part by developing assays and workflows that researchers and therapeutic developers can use to rapidly discover antibodies that are key to treatments."

About Vanderbilt University Medical CenterVanderbilt University Medical Center (VUMC) is one of the nation's largest academic medical centers. As part of its research enterprise, in partnership with the Vanderbilt University School of Medicine, the Vanderbilt Vaccine Center is participating in the US Defense Advanced Research Projects Agency's (DARPA's) Pandemic Protection Platform (P3) program, a five-year cooperative agreement to develop protective antibody treatments that can be rushed to health care providers within 60 days after the outbreak of viral diseases anywhere in the world.

About La Jolla Institute for Immunology La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease.

About Emory UniversityEmory University is one of the world's leading research universities. Its mission is to create, preserve, teach and apply knowledge in the service of humanity. The Emory effort is led by Dr. Lee of the Pulmonary, Allergy, Critical Care & Sleep Division, The Lowance Center for Human Immunology and the Emory Vaccine Center. She contributes culture methods developed in her lab that greatly improve the survival of B cells and plasma cells thereby facilitating the isolation of extremely rare cells producing the antibodies of interest.Dr. Lee's work is supported by NIH, the Lowance Center, Gates Foundation, and the Georgia Research Alliance.

About Berkeley LightsHere at Berkeley Lights, we think cells are awesome! Cells are capable of manufacturing cures for diseases, fibers for clothing, energy in the form of biofuels, and food proteins for nutrition. So the question is, if nature is capable of manufacturing the products we need in a scalable way, why aren't we doing more of this? Well, the answer is that with the solutions available today, it is hard. It takes a long time to find the right cell for a specific job, costs lots of money, and if you have picked a suboptimal cell line, has a very low process yield. Berkeley Lights has the complete solution to find the best cells by functionally screening and recovering individual cells for antibody discovery, cell line development, T cell analysis, and synthetic biology. Our proprietary technology, including the Beacon and Lightning platforms accelerate the rate you can discover and develop cell-based products in a fraction of the time and at a fraction of the cost of conventional, legacy research methods. Using our tools and solutions, scientists can find the best cells, the first time they look. For more information, visit http://www.berkeleylights.com.

Berkeley Lights' Beacon and Lightning systems and Culture Station instrument are:

For Research Use Only. Not for use in diagnostic procedures.

View original content to download multimedia:http://www.prnewswire.com/news-releases/berkeley-lights-announces-the-global-emerging-pathogen-antibody-discovery-consortium-gepad-to-attack-covid-19-and-other-viruses-301029500.html

SOURCE Berkeley Lights

Link:
Berkeley Lights Announces the Global Emerging Pathogen Antibody Discovery Consortium (GEPAD) to Attack COVID-19 and Other Viruses - Yahoo Finance

Beyond the Surface – Uncovering the Layers of Immune Cell Complexity – Technology Networks

Application NoteMar 25, 2020

Immunology and infectious disease research continues to advance our understanding of significant health issues including cancer, autoimmune diseases, and emerging pathogens. However, the field faces significant challenges due to the complex nature of the immune system and the limitations of prevailing research tools.

In order to comprehensively understand the immune response, scientists need the ability to characterize cell types and functional states in individual cells at high throughput.

In this app note, discover flexible solutions to the challenges of immunological studies, allowing you to:

More here:
Beyond the Surface - Uncovering the Layers of Immune Cell Complexity - Technology Networks

Harvard Prof.: Don’t Count On A COVID-19 Vaccine In 12 To 18 Months – WBUR

Take a step back from the breakneck COVID-19 news cycle and it doesn't take much to wonder: How long is this pandemic going to last and ultimately, what can be done to stop it?

To better-understand the long-term outlook for the novel coronavirus and the trade-offs inherent in our current social-distancing strategy, WBUR spoke with Michael Mina, an assistant professor of epidemiology at Harvard specializing in immunology and infectious diseases.

Minas research focuses on the life-history of infectious pathogens, and he begins with the concept of herd immunity."

On how "herd immunity" works

Herd immunity is actually quite a simple idea, in that once there are enough people in the population who have been exposed to the virus or perhaps in other cases, a vaccine so that they are immune, then each one of those people that is immune becomes almost like a firebreak for preventing spread.

So if you walk into a room, for example, and everyone is susceptible to a virus and you bring that virus in, then there's no herd immunity. And on average, you'll infect two or three people. But if 90% of the room is immune already, then it's unlikely that when you walk into that room, you'll infect more than one person because most of the people you bump into will already be immune.

On whether the coronavirus that causes COVID-19 is susceptible to herd immunity

Absolutely. That's one of the great things about herd immunity, is that as long as people can individually become immune to the virus, then herd immunity is possible. And for this particular virus, it's about 65% of the population that might need to be immune before we actually can really inhibit further spread of the virus.

On the importance of establishing herd immunity vs. social distancing

That's a very good and somewhat controversial question. Essentially, a different way to put it is, 'Could we just get lots of younger people infected with this virus so that they can no longer necessarily transmit it?' And because we know that younger people maybe don't experience as severe a disease as older people, that would be a benefit.

The problem there is we know that actually, younger people can still get very sick and can die. But I think that there are some takeaways that we could get from this idea: One small slice of that question might be: 'Well, if we know that there are a number of young people who have already been infected and are immune, then maybe they can be the ones who are the nurses for people in a nursing home,' for example.

But I think it is a controversial idea to just say that all young people should go out and get infected in order to confer greater herd immunity because we know that it still is a dangerous virus even for the young people in this population.

On the balancing act we need to achieve to prevent spread

That's one of the real dilemmas we find ourselves in today. I've been astounded to see just how much social distancing is happening, at least in some of our states and cities; and this is really terrific. This is what is needed at this moment in time to prevent ... a collapse of the health care system, if you will, in terms of the hospitals getting overridden with people.

But the problem with doing such a good job right now is that we might come out of this wave of the epidemic with less than 2% of the population infected. And as a population, we'll be just as susceptible, say, come the fall, as we were a few months ago.

On the necessity of social distancing at this particular point in time

Because this virus came into our population pretty quickly and then we kind of squandered a couple of months in figuring out how to deal with it ... now we're trying to catch up, if you will, to really control some of our essential services, like ensuring that we have enough ICU beds and ventilators for all the people who might need them. We just are trying to buy some time so that we can deal with it more appropriately in a more prepared way, maybe in a few months from now.

On whether an effective vaccine is likely in 12 to 18 months

Twelve to 15 months has been a timeframe that's been passed around as a minimum that it could take to develop a vaccine and bring it to market. But there's a caveat out there. That 12-to-15-month timeframe assumes that the vaccine actually works and protects us. But that's actually really the hard part ... finding the right combination of things to put in the vaccine to make sure that it elicits a good amount of immunological protection. And so it could be that 12 months from now, we're starting back at ground zero with a new trial.

I think that 12 to 15 months is probably not the most realistic timeframe. I anticipate that it will be quite a bit longer, if ever. And it's important to remember that we don't have any useful vaccines currently for many of the seasonal viruses that we see every year.

More:
Harvard Prof.: Don't Count On A COVID-19 Vaccine In 12 To 18 Months - WBUR

Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update – Yahoo Finance

Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020

Cash, cash equivalents and marketable securities totaled $401.8 million at year-end 2019

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.

"Our hearts are with the patients, families, caregivers and medical professionals suffering and sacrificing in the ongoing Covid-19 viral pandemic. We are monitoring the situation on a daily basis to understand the impact on Gossamer and our programs and are taking the necessary actions now to do what is best for our patients, employees and company," said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer Bio.

"2019 was a year of execution for Gossamer Bio, as we continued to advance all four of our clinical-stage product candidates in our target areas of immunology, inflammation and oncology. Notwithstanding the Covid-19 pandemic, we expect to continue our momentum in 2020, with data from all of our candidates expected this year. We are committed to advancing our product candidates and the field of medicine for the betterment of patients and their families, and we look forward to providing updates on these efforts throughout the year."

Clinical-Stage Product Candidate Updates

GB001: Oral DP2 Antagonist for Eosinophilic Asthma and Chronic Rhinosinusitis (CRS)

GB002: Inhaled PDGFR Inhibitor for Pulmonary Arterial Hypertension (PAH)

GB004: Oral HIF-1 Stabilizer for Inflammatory Bowel Disease

GB1275: Oral CD11b Modulator for Oncology Indications

Financial Results for Quarter and Full Year Ended December 31, 2019

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

Forward-Looking Statements

Gossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Companys current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing of initiation and enrollment of clinical trials for our product candidates; plans to rapidly advance our product candidates; expectations on the timing of data readouts from our clinical studies; the potential clinical benefits of our product candidates; the indications we intend to pursue and our related business strategies; the expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities; and access to the Companys senior debt facility. The inclusion of forward-looking statements should not be regarded as a representation by Gossamer that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Gossamers business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the recent global outbreak of the Covid-19 pandemic; the Companys dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Gossamers clinical trials and preclinical studies for its product candidates; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of the Companys product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Gossamers ability to obtain and maintain intellectual property protection for its product candidates; Gossamers ability to comply with its obligations in collaboration agreements with third parties or the agreements under which it licenses intellectual property rights from third parties; the risk that the funding under the senior debt facility may not be completed on the timeframe Gossamer expects, or at all, including as a result of Gossamer's failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the credit facility; and other risks described in the Companys prior press releases and the Companys filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the Companys annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

GOSSAMER BIO, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA

(UNAUDITED; IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

Three months ended December 31,

Year Ended December 31,

STATEMENTS OF OPERATIONS DATA:

2019

2018

2019

2018

Operating expenses:

Research and development

$

42,596

$

25,872

$

143,403

$

55,283

In process research and development

1,600

-

Read the original:
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update - Yahoo Finance

How Cornell Departments Are Helping in the Fight Against Coronavirus – Cornell University The Cornell Daily Sun

With the spread of COVID-19 affecting communities across the nation and recently even Cornells campus itself a wide range of academic departments are doing what they can to help during the pandemic.

Labs in the College of Veterinary Medicine run by Profs. Brian VanderVen and David Russell, microbiology and immunology have donated over 600 respirator masks to Cayuga Medical Center amid a national shortage of protective medical gear.

VanderVen explained that they had started stockpiling masks earlier in the year, fearing that a future supply-chain problem could result in a lack of necessary protection for those in the lab.

However, the lab ultimately found alternate ways of protecting themselves and donated the masks to physicians on the front lines.

We certainly could still use them, VanderVen said. But the clinicians are going to need them more than us.

The lab is still exploring ways of helping Cayuga Medical beyond its initial donation, according to VanderVen. For instance, longer-term, faculty across Cornells immunology department are looking at new ways to diagnose and treat coronavirus, he said.

Other University labs have been asked to donate supplies in the fight against COVID-19, including one run by Prof. Maureen Hanson, molecular biology, whose lab donated 3,000 pairs of nitrile gloves to be distributed as necessary by the Tompkins County Health Department.

After hearing about the nationwide mask shortage, Prof. C.C. Chu, fiber science and apparel design, emailed colleagues with an idea.

I thought, we have a design component to the department, maybe they can use their knowledge and expertise to make surgical masks? he said.

Beyond developing more efficient mask design, Chu hopes to see a prior research interest of his revived in the fight against the pandemic. In the late 2000s, his lab developed a family of pseudo-protein biomaterials that a company eventually licensed to develop synthetic vaccines.

The synthetic vaccine technology based on my labs pseudo-protein biomaterials is still there, Chu said. If someone would have enough resources, this synthetic vaccine technology can be reactivated again to help the fast development of the COVID-19 vaccine.

Some Cornell labs are also doing their part by continuing ongoing research.

Prof. Matthew DeLisa, chemical and biomolecular engineering, said his lab is working on National Institutes of Health-funded research that could assist in efforts to better model and understand the spread of COVID-19.

Insight gained here could guide vaccine design and development, DeLisa said.

DeLisas colleague, Prof. Susan Daniel, chemical and biomolecular engineering, runs a lab whose research is so relevant right now that she applied for an exemption that will enable her to continue work despite the campus shutdown.

The focus of this project is to understand how coronavirus enters its host cell and specifically how the spikes that decorate the virus facilitate that entry, Daniel explained.

Stemming from that work, her lab is now screening drugs that could inhibit the virus infection, developing antibodies and small molecules that could more effectively block its entry into human cells.

Visit link:
How Cornell Departments Are Helping in the Fight Against Coronavirus - Cornell University The Cornell Daily Sun

Possible COVID-19 treatment: transfusion of antibodies from recovered patients’ blood | The Source – Washington University in St. Louis Newsroom

With no drugs or vaccines yet approved for COVID-19 and the number of U.S. cases increasing by the thousands every day, doctors are looking to revive a century-old therapy for infectious diseases: transfusing antibodies from the blood of recovered patients into people who are seriously ill.

During the Spanish flu pandemic of 1918, doctors were faced with a deadly illness and no specific treatments. Recognizing that people who had recovered were immune to the infection, some doctors tried treating their patients with blood serum from recovered flu patients. In many cases it worked.

Giving serum from newly recovered patients is a stone-age approach, but historically it has worked, saidJeffrey P. Henderson, MD, PhD, associate professor of medicine and of molecular microbiology at Washington University School of Medicine in St. Louis. This is how we used to prevent and treat viral infections like measles, mumps, polio and influenza, but once vaccines were developed, the technique understandably fell out of favor and many people forgot about it. Until we have specific drugs and vaccines for COVID-19, this approach could save lives.

Henderson was reminded of the technique by Arturo Casadevall, MD, PhD, the chair of molecular microbiology and immunology at Johns Hopkins Bloomberg School of Public Health in Baltimore. Casadevall began championing the idea of using plasma from convalescing patients to treat COVID-19 in early March. Plasma and serum are both the clear fluid portion of blood, and both contain antibodies, but plasma also contains some other proteins lacking in serum.

Plasma transfusion was used experimentally to treat small numbers of people during the SARS outbreak of 2002 and 2003. SARS, which stands for severe acute respiratory syndrome, is caused by a coronavirus closely related to the one that causes COVID-19. In one study, SARS patients who received plasma transfusions recovered faster than those who did not.

Henderson, Casadevall and Michael Joyner, MD, a physiologist at the Mayo Clinic in Rochester, Minn., quickly joined forces and leveraged the resources at their three institutions to test the approach. Their efforts resulted in an investigational new drug application to the Food and Drug Administration that was filed March 18. If the application is approved, they plan to move rapidly to a clinical trial.

This is something that can be done very quickly, much faster than drug development, because it basically involves donating and transfusing plasma, Henderson said. As soon as we have individuals who have recovered from COVID-19 walking around, we have potential donors, and we can use the blood bank system to obtain plasma and distribute it to the patients who need it.

The plan is to ask patients who recover from COVID-19 to donate their blood, from which plasma would be isolated. After screening for toxins and viruses, the plasma would be transfused into people ill with or at high risk of COVID-19. The procedure for isolating plasma is a long-established technology that can be performed using equipment normally found in blood-banking facilities, and receiving plasma from these donors is as safe as any other plasma transfusion, Henderson said.

The concept is simple, but the execution is more complicated. The scientists still need to determine how much antibody is in the blood of recovered patients, and how much antibody needs to be given to effectively treat or prevent COVID-19.Brenda Grossman, MD, professor of pathology and immunology at Washington University School of Medicine and director of transfusion medicine at Barnes-Jewish Hospital, was brought on board to help navigate the complex regulations surrounding blood donations and transport of blood products across state lines.

The idea is catching fire.

Last week, it was the three of us on a conference call, Henderson said. This week, we had people from all over the country I dont even know how many. Everyones excited about this. If it works, it could provide a lifeline at this early stage of the pandemic.

WashU Response to COVID-19Visit coronavirus.wustl.edu for the latest information about WashU updates and policies. See all stories related to COVID-19.

Originally published by the School of Medicine

Read more:
Possible COVID-19 treatment: transfusion of antibodies from recovered patients' blood | The Source - Washington University in St. Louis Newsroom

New Research Shows That Human Working Memory can be Tweaked With Non-Invasive Magnetic Stimulation – Technology Networks

A group of scientists from the Research Center of Neurology and Skoltech showed that human working memory can be tweaked using non-invasive magnetic stimulation of the brain. Also, they discovered that the effect of magnetic stimulation weakens as the brain works on a cognitive task under stimulation. The results of their study were published in the journal Brain Sciences.

Working memory (WM) stores and processes the information we need for daily use. The WM mechanisms get activated when, for example, we memorize a phone number until we find a scrap of paper or a smartphone to write it down. WM disorders are a frequent occurrence in many nervous system diseases, whereas in healthy people, the WM capacity is associated with an individuals learning ability and general intelligence level.

The transcranial magnetic stimulation (TMS) is regarded as one of the promising non-pharmacological WM enhancement methods leveraging the effect of the alternating magnetic field which painlessly penetrates through the scalp and skull bones, with an electric field forming in the cortex. As TMS can influence the mechanisms of neuroplasticity, it is used as a therapeutic method for various nervous system diseases. The TMS effects are known to depend both on the stimulation parameters and the brain activity during stimulation. Combining TMS with concurrent cognitive activity has evolved into a cognitive enhancement technique for patients with Alzheimers disease. However, data are still lacking on how exactly the brain activity influences the TMS efficiency.

The researchers compared the effects of TMS on WM when stimulation was applied with and without a cognitive load. The WM performance was evaluated before and after a 20-minute stimulation session. The stimulation area was selected based on the individual brain activation pattern which formed during a WM-engaging task. The results suggest that WM does not respond to any stimulation other than TMS with no cognitive load.

The results of our research lead us to conclude that cognitive activity can reduce rather than increase the TMS efficiency. This should be borne in mind when developing new stimulation protocols for cognitive enhancement in both healthy volunteers and patients suffering from various nervous system diseases, says Natalya Suponeva, Head of Department of Neurorehabilitation and Physiotherapy at the Research Center of Neurology and Associate Member of RAS.

Maxim Fedorov, Director of the Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE), is inspired by the research outcomes and the ensuing opportunities: The results attest to the efficiency of interdisciplinary research in biomedicine and cognitive sciences, benefiting from advanced data processing methods. We at CDISE have much interest in collaborating with the Research Center of Neurology and studying WM mechanisms for a number of reasons. First, this would be an exciting experience and a good opportunity to apply some of the findings in practice in the short term (better memory is what many of us need). Second, modern biomedical research tools open up broad horizons for data and AI scientists. Data are abundant but sometimes too noisy and the data samples are often heterogeneous. Generally speaking, we are faced with non-trivial tasks that prompt ideas for new research targets in our field. Third, many ideas in Big Data and AI, such as neural networks, were born out of research into the human higher nervous activity. And this is very interesting. Currently, we are busy working on many projects at the crossroads of neuroscience, simulation and Big Data. Personally, I believe that man is as boundless as the Universe, and we are just beginning to understand how interesting we are and how much potential we have. I am convinced that we have a lot of unexpected discoveries ahead of us. We strongly hope that our collaboration with the Research Center of Neurology will be a continued success.

Currently, the study is moving forward with a larger number of healthy volunteers in order to validate the recent findings and evaluate the long-term effect of TMS on WM performance.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More here:
New Research Shows That Human Working Memory can be Tweaked With Non-Invasive Magnetic Stimulation - Technology Networks

Anatomy of a frogfish: New book explores world of fishes with arms and legs – UW News

Research | Science | UW and the community | UW Notebook

March 23, 2020

An illustration of the frogfish Antennarius pictus, published by George Shaw in 1794. From a new book by Ted Pietsch, UW professor of emeritus of aquatic and fishery sciences.

Any old fish can swim. But what fish can walk, scoot, clamber over rocks, change color or pattern and even fight? That would be the frogfish.

Frogfishes: Biodiversity, Zoogeography, and Behavioral Ecology was published in March by Johns Hopkins University Press.Johns Hopkins University Press

The latest book by Ted Pietsch, UW professor emeritus of aquatic and fishery sciences, explores the lives and habits of these unusual marine shorefishes. Frogfishes: Biodiversity, Zoogeography, and Behavioral Ecology was published in March by Johns Hopkins University Press.

Pietsch, who is also curator emeritus of fishes at the Burke Museum of Natural History and Culture, has published over 200 articles and a dozen books on the biology and behavior of marine fishes. He wrote this book with Rachel J. Arnold, a faculty member at Northwest Indian College in Bellingham and its Salish Sea Research Center.

Ted Pietsch

These walking fishes have stepped into the spotlight lately, with interest growing in recent decades. And though these predatory fishes will almost certainly devour anything else that moves in a home aquarium, Pietsch writes, a cadre of frogfish aficionados around the world has grown within the dive community and among aquarists. In fact, Pietsch said, there are three frogfish public groups on Facebook, with more than 6,000 members.

UW Notebook caught up with Pietsch for a conversation about his book and the unusual family of fishes it describes.

First, what is a frogfish?

Ted Pietsch: A member of a family of bony fishes, containing 52 species, all of which are highly camouflaged and whose feeding strategy consists of mimicking the immobile, inert, and benign appearance of a sponge or an algae-encrusted rock, while wiggling a highly conspicuous lure to attract prey.

Frogfish are highly camouflaged; their feeding strategy involves mimicking the immobile, benign appearance of a sponge or an algae-encrusted rock, while wiggling a conspicuous lure to attract prey. Which here is sponge and which is frogfish?(If you guessed that the sponge is on the right, you were correct.)Andrew Taylor

This is a fish that walks and hops across the sea bottom, and clambers about over rocks and coral like a four-legged terrestrial animal but, at the same time, can jet-propel itself through open water. Some lay their eggs encapsulated in a complex, floating, mucus mass, called an egg raft, while some employ elaborate forms of parental care, carrying their eggs around until they hatch.

They are among the most colorful of natures productions, existing in nearly every imaginable color and color pattern, with an ability to completely alter their color and pattern in a matter of days or seconds. All these attributes combined make them one of the most intriguing groups of aquatic vertebrates for the aquarist, diver, and underwater photographer as well as the professional zoologist.

Thats interesting about their changing color and pattern. What determines the shade or pattern the fish adopts, and how quickly?

T.P.: The abilityto change coloration varies enormously among species. The SargassumFrogfish, for instance, can alter hue and patternalmost instantly, especially in response tostimulation, like courtship, spawning behavior, or aggression between competing males for which this species is famous they fight until death!

Other frogfishes are more limitedin terms of the rate of change, but most are able to take on a nearly fullrange of coloration from drab to highly colorfulwithina period of a few days, weeks, or months,usually in response to their surroundings, that is, to better hide themselves among rocks, coral, or sponges, etc. In many species radical chromatic variety and changeseems almost infinite.

Do frogfish use their appendages for other purposes as well?

T.P.: The arms and legs are used for walking and climbing over rocks and coral, but they also serve as planing devices when swimming in open water, for steering and braking.

Where do frogfishes live?

T.P.: Frogfishes are found just about everywhere in shallow-water, tropical and subtropical habitats of all major seas and oceans of the world, except the Mediterranean Sea, and why not the latter, no one seems to know for sure.

Who discovered the frogfish, and when?

T.P.: Knowledge of frogfishes began to accumulate sometime prior to the year 1630, when an unknown Dutchman made a drawing of a strange fish that was observed on the coast of Maranho, northeastern Brazil.

A woodcut of a strange fish seen off the coast of Northeastern Brazil and published in 1633 under the name Pira Vtoewah, forma monstrosa. Artist unknown.

A woodcut was made from this drawing and published in 1633 under the name Pira Vtoewah, forma monstrosa.

Somewhat later, and on the other side of the world, another Dutchman, Captain Willem de Vlamingh, and his crew aboard the frigate Geelvinck were searching for survivors of a shipwreck off the coast of Western Australia. On the morning of December 29, 1696, amid discoveries of rats as big as common house cats (now known to be wallabies) and tracks of tigers and other ferocious beasts (dingoes), there was observed a remarkable fish, about two feet long, with a round head and a sort of arms and legs and even something like hands. No doubt this was a frogfish, the earliest published mention of a frogfish from the Indo-Pacific region.

How did your work bring you to study frogfishes?

T.P.: My interest in fishes began a long time ago, when, as a first-year graduate student at the University of Southern California, I was asked by my major professor to take part in shipboard collecting trips off the coast of Southern California. I thought I wanted to study snakes, but, when it came to fishes, I was immediately overwhelmed with the tremendous diversity of forms and their amazing adaptations I forgot about snakes and never looked back. I became especially interested in fishes that lie-in-wait and attract their prey using luring devices, thus frogfishes became my ideal research animal.

As you note in the introduction, a lot of new information about frogfishes has accumulated since the first publication of this work, in 1987. What are some of the improvements and updates in this greatly revised new edition?

The earliest published images of two species of frogfishes, published by zoologist Albertus Seba (1665-1736).

T.P.: Over the past three decades, an enormous amount of new information about frogfishes has accumulated and all of it is addressed in this thoroughly revised edition: new species have been discovered, described, and formally named; geographic distributions have been expanded as marine habitats and ecosystems have been more thoroughly explored; new molecular techniques and greater phylogenetic understanding have resulted in new and sometimes unexpected perspectives on evolutionary relationships; and new insights into feeding, locomotion, and especially reproductive behavior have been observed and recorded through an ever-expanding, worldwide interest in underwater research by students and professional scientists as well as aquarists and recreational divers.

While 30 years ago it was difficult to find high-quality color photographs of frogfishes, state-of-the-art digital camera equipment and talented photographers everywhere have flooded the Internet with a multitude of astonishing images, both stills and videos.

You write that conservation is addressed in this edition what are the conservation concerns regarding the frogfish?

T.P.: Thirty years ago, it did not occur to us to include a discussion of conservation, but it appears in this volume. Characterized by low population densities, restricted and patchy geographic distributions, small home ranges, and limited mobility, frogfishes are particularly vulnerable to population declines and risk of extinction due to competition from invasive species, over-collecting by aquarists and the tropical fish trade, climate change (global warming), and habitat degradation. The book looks at efforts to address these threats.

A painting of Sambia, the Walking-fish or Common Fish of Ambon. One of hundreds of paintings made in the late 1690s and very early 1700s by Samuel Fallours, an artist working for the Dutch East India Company at Ambon, Indonesia. He is said to have modeled this bizarre depiction of an antennariid exactly from nature. Fallours legend to his illustration reads: I caught it on the sand and kept it alive in my house for three days; it followed me everywhere with great familiarity, much like a little dog. Mr. Scott in Amsterdam has one preserved in spirits of wine.Published by Louis Renard in 1719

Can you talk a bit about the extensive research that went into this volume?

Work toward completion of this volume has been on-going for decades. The most time-consuming part of it, but perhaps also the most enjoyable, was extensive travel to all the great museum collections around the world that contain preserved specimens of frogfishes.

Just under 5,000 specimens were examined, their structure evaluated, measured, parts counted, and recorded. We also recorded who, when, where and how each specimen was collected. This edition also required an exhaustive review of the published literature over the past 30 years.

Last, but by no means least, were the incredible contributions from museum curators, aquarists, divers, and underwater photographers who generously provided information and photographs. Altogether, some 175 photographers contributed images, more than 7,000 in total, each asking for nothing more than a note of thanks. This volume would be nothing without them.

What is the audience for this book?

Our intended audience is the scientific community. Ichthyologists and herpetologists, marine ecologists, evolutionary biologists, systematists, behaviorists, biogeographers, conservationists, science historians, commercial tropical fish traders, public and private aquarists, scuba divers, underwater photographers, and natural history enthusiasts in general.

UW Notebook is a section of the UW News site dedicated to telling stories of the good work done by faculty and staff at the University of Washington. Read all posts here.

See the original post here:
Anatomy of a frogfish: New book explores world of fishes with arms and legs - UW News